- Home
- GRI vs CNSP Comparison
GRI vs CNSP Comparison
Compare GRI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- CNSP
- Stock Information
- Founded
- GRI 2018
- CNSP 2017
- Country
- GRI United States
- CNSP United States
- Employees
- GRI N/A
- CNSP N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- GRI Health Care
- CNSP Health Care
- Exchange
- GRI Nasdaq
- CNSP Nasdaq
- Market Cap
- GRI 3.2M
- CNSP 5.6M
- IPO Year
- GRI N/A
- CNSP 2019
- Fundamental
- Price
- GRI $1.29
- CNSP $0.84
- Analyst Decision
- GRI Strong Buy
- CNSP Hold
- Analyst Count
- GRI 2
- CNSP 1
- Target Price
- GRI $22.00
- CNSP N/A
- AVG Volume (30 Days)
- GRI 109.0K
- CNSP 224.3K
- Earning Date
- GRI 08-13-2025
- CNSP 08-13-2025
- Dividend Yield
- GRI N/A
- CNSP N/A
- EPS Growth
- GRI N/A
- CNSP N/A
- EPS
- GRI N/A
- CNSP N/A
- Revenue
- GRI N/A
- CNSP N/A
- Revenue This Year
- GRI N/A
- CNSP N/A
- Revenue Next Year
- GRI N/A
- CNSP N/A
- P/E Ratio
- GRI N/A
- CNSP N/A
- Revenue Growth
- GRI N/A
- CNSP N/A
- 52 Week Low
- GRI $1.10
- CNSP $0.73
- 52 Week High
- GRI $43.69
- CNSP $148.00
- Technical
- Relative Strength Index (RSI)
- GRI 41.20
- CNSP 38.65
- Support Level
- GRI $1.20
- CNSP $0.73
- Resistance Level
- GRI $1.45
- CNSP $0.84
- Average True Range (ATR)
- GRI 0.10
- CNSP 0.07
- MACD
- GRI 0.02
- CNSP 0.00
- Stochastic Oscillator
- GRI 36.00
- CNSP 31.47
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.